Establishment of In Vitro P-Glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug-drug interaction at the drug discovery stage

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 4013-4023

  Sugimoto, Hiroshi ^a   Matsumoto, Shin ichi ^a   Tachibana, Miho ^a   Niwa, Shin ichi ^a   Hirabayashi, Hideki ^a   Amano, Nobuyuki ^a   Moriwaki, Toshiya ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Digoxin; Drug interactions; In vitro models; Mathematical model; P glycoprotein; P gp inhibition; Pharmacokinetics; Risk assessment for DDI; Transporters

Indexed keywords

ASTEMIZOLE; BEPRIDIL; CARVEDILOL; CHLORPROMAZINE; CYCLOSPORIN A; DIGOXIN; DILTIAZEM; ELACRIDAR; FELODIPINE; GLYCOPROTEIN P; ISRADIPINE; ITRACONAZOLE; KETOCONAZOLE; LAPATINIB; LOPERAMIDE; MEMANTINE; MIBEFRADIL; MIDAZOLAM; NICARDIPINE; NIFEDIPINE; NITRENDIPINE; PROPRANOLOL; QUINIDINE; QUININE; SERTRALINE; SIMVASTATIN; SPIRONOLACTONE; UNINDEXED DRUG; VERAPAMIL; VINBLASTINE;

ARTICLE; CELL MEMBRANE; COMPARTMENT MODEL; CONCENTRATION RESPONSE; DRUG DETERMINATION; DRUG DRUG INTERACTION; DRUG INTERACTION; DRUG PROTEIN BINDING; DRUG TRANSPORT; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; HUMAN; HUMAN TISSUE; IC 50; INHIBITION KINETICS; MEMBRANE TRANSPORT; PLASMA PROTEIN BINDING; PROTEIN EXPRESSION; RISK ASSESSMENT;

EID: 79960150931     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22652     Document Type: Article

References (39)

1. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
2. Tsuji A, Terasaki T, Takabatake Y, Tenda Y, Tamai I, Yamashima T, Moritani S, Tsuruo T, Yamashita J. 1992. P-glycoprotein as the drug efflux pump in primary cultured bovine brain capillary endothelial cells. Life Sci 51(18):1427-1437.
3. Schinkel AH, Jonker JW. 2003. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: An overview. Adv Drug Deliv Rev 55(1):3-29.
4. Lee CA, Cook JA, Reyner EL, Smith DA. 2010. P-glycoprotein related drug interactions: Clinical importance and a consideration of disease states. Expert Opin Drug Metab Toxicol 6(5):603-619.
5. Sugimoto H, Hirabayashi H, Kimura Y, Furuta A, Amano N, Moriwaki T. 2011. Quantitative investigation of the impact of P-glycoprotein inhibition on drug transport across blood-brain barrier in rats. Drug Metab Dispos 39(1):8-14.
6. Wacher VJ, Wu CY, Benet LZ. 1995. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: Implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13(3):129-134.
7. Cook CS, Berry LM, Burton E. 2004. Prediction of in vivo drug interactions with eplerenone in man from in vitro metabolic inhibition data. Xenobiotica 34(3):215-228.
8. Tsuji A. 2002. Transporter-mediated drug interactions. Drug Metab Pharmacokinet 17(4):253-274.
9. Keogh JP, Kunta JR. 2006. Development, validation and utility of an in vitro technique for assessment of potential clinical drug-drug interactions involving P-glycoprotein. Eur J Pharm Sci 27(5):543-554.
10. Rautio J, Humphreys JE, Webster LO, Balakrishnan A, Keogh JP, Kunta JR, Serabjit-Singh CJ, Polli JW. 2006. In vitro P-glycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: A recommendation for probe substrates. Drug Metab Dispos 34(5):786-792.
11. Adachi Y, Suzuki H, Sugiyama Y. 2001. Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res 18(12):1660-1668.
12. Yamazaki M, Neway WE, Ohe T, Chen I, Rowe JF, Hochman JH, Chiba M, Lin JH. 2001. In vitro substrate identification studies for P-glycoprotein-mediated transport: Species difference and predictability of in vivo results. J Pharmacol Exp Ther 296(3):723-735.
13. Zhang L, Zhang YD, Strong JM, Reynolds KS, Huang SM. 2008. A regulatory viewpoint on transporter-based drug interactions. Xenobiotica 38(7-8):709-724.
14. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, Kumar G, McLeod J, Obach RS, Roberts S, Roe A, Shah A, Snikeris F, Sullivan JT, Tweedie D, Vega JM, Walsh J, Wrighton SA. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31(7):815-832.
15. Feng B, Mills JB, Davidson RE, Mireles RJ, Janiszewski JS, Troutman MD, de Morais SM. 2008. In vitro P-glycoprotein assays to predict the in vivo interactions of P-glycoprotein with drugs in the central nervous system. Drug Metab Dispos 36(2):268-275.
16. Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, Lee CA. 2009. Drug-drug interactions mediated through P-glycoprotein: Clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther 85(2):173-181.
17. Takeuchi T, Yoshitomi S, Higuchi T, Ikemoto K, Niwa S, Ebihara T, Katoh M, Yokoi T, Asahi S. 2006. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1. Pharm Res 23(7):1460-1472.
18. Klein TE, Chang JT, Cho MK, Easton KL, Fergerson R, Hewett M, Lin Z, Liu Y, Liu S, Oliver DE, Rubin DL, Shafa F, Stuart JM, Altman RB. 2001. Integrating genotype and phenotype information: An overview of the PharmGKB project. Pharmacogenetics research network and knowledge base. Pharmacogenomics J 1(3):167-170.
19. Brunton L, Lazo J, Parker K, Eds. 2005. Goodman & Gilman's The pharmacological basis of therapeutics. 11th ed. McGraw-Hill Publishers, New York.
20. Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, Surry DD. 2011. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: A case study for AZD5672. Drug Metab Dispos 39(2):275-282.
21. Adachi Y, Suzuki H, Sugiyama Y. 2003. Quantitative evaluation of the function of small intestinal P-glycoprotein: Comparative studies between in situ and in vitro. Pharm Res 20(8):1163-1169.
22. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y. 2009. Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39(6):430-443.
23. Dupont AG. 1993. Renal haemodynamics in hypertension: Effects of antihypertensive drugs. J Hum Hypertens 7 Suppl 1:S42-S45.
24. Breimer DD. 2008. PK/PD modelling and beyond: Impact on drug development. Pharm Res 25(12):2720-2722.
25. Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S, Ishizaki T. 2000. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: Evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol 56(9-10):643-649.
26. Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S. 2010. Prediction of the intestinal first-pass metabolism of CYP3A substrates in humans using cynomolgus monkeys. Drug Metab Dispos 38(11):1967-1975.
27. Kirimli O, Kalkan S, Guneri S, Tuncok Y, Akdeniz B, Ozdamar M, Guven H. 2001. The effects of captopril on serum digoxin levels in patients with severe congestive heart failure. Int J Clin Pharmacol Ther 39(7):311-314.
28. Mendes J, Martinho A, Simoes O, Mota A, Breitenfeld L, Pais L. 2009. Genetic polymorphisms in CYP3A5 and MDR1 genes and their correlations with plasma levels of tacrolimus and cyclosporine in renal transplant recipients. Transplant Proc 41(3):840-842.
29. Foradori A, Mezzano S, Videla C, Pefaur J, Elberg A. 1998. Modification of the pharmacokinetics of cyclosporine A and metabolites by the concomitant use of Neoral and diltiazem or ketoconazol in stable adult kidney transplants. Transplant Proc 30(5):1685-1687.
30. Tuteja S, Alloway RR, Johnson JA, Gaber AO. 2001. The effect of gut metabolism on tacrolimus bioavailability in renal transplant recipients. Transplantation 71(9):1303-1307.
31. Malingre MM, Beijnen JH, Rosing H, Koopman FJ, Jewell RC, Paul EM, Ten Bokkel Huinink WW, Schellens JH. 2001. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br J Cancer 84(1):42-47.
32. Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. 2000. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68(1):6-12.
33. Kirby B, Kharasch ED, Thummel KT, Narang VS, Hoffer CJ, Unadkat JD. 2006. Simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities. J Clin Pharmacol 46(11):1313-1319.
34. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Trugnan G, Becquemont L. 2003. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 73(1):51-60.
35. Schwartz JI, Agrawal NG, Wehling M, Musser BJ, Gumbs CP, Michiels N, De Smet M, Wagner JA. 2008. Evaluation of the pharmacokinetics of digoxin in healthy subjects receiving etoricoxib. Br J Clin Pharmacol 66(6):811-817.
36. Miyakawa T, Shionoiri H, Takasaki I, Kobayashi K, Ishii M. 1991. The effect of captopril on pharmacokinetics of digoxin in patients with mild congestive heart failure. J Cardiovasc Pharmacol 17(4):576-580.
37. Schwartz JI, De Smet M, Larson PJ, Verbesselt R, Ebel DL, Lins R, Lens S, Porras AG, Gertz BJ. 2001. Effect of rofecoxib on the pharmacokinetics of digoxin in healthy volunteers. J Clin Pharmacol 41(1):107-112.
38. US Department of Health and Human Services FaDA. 2005. Ramelteon-FDA approval package, medical/clinical review 021782/S-000.
39. Vaidyanathan S, Camenisch G, Schuetz H, Reynolds C, Yeh CM, Bizot MN, Dieterich HA, Howard D, Dole WP. 2008. Pharmacokinetics of the oral direct renin inhibitor aliskiren in combination with digoxin, atorvastatin, and ketoconazole in healthy subjects: The role of P-glycoprotein in the disposition of aliskiren. J Clin Pharmacol 48(11):1323-1338.